NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
David S. Ettinger, Dara L. Aisner, Douglas E. Wood et al. · Journal of the National Comprehensive Cancer Network · 2018
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.
Cited by 463 works. doi:10.6004/jnccn.2018.0062 Open-access PDF
Authors
- David S. Ettinger
- Dara L. Aisner
- Douglas E. Wood
- Wallace Akerley
- Jessica Ruth Bauman
- Joe Yujiao Chang
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Thomas J. Dilling
- M.C. Dobelbower
- Ramaswamy Govindan
- Matthew A. Gubens
- Mark W. Hennon
- Leora Horn
- Rudy P. Lackner
- Michael D. Lanuti
- Ticiana A.B. Leal
- Rogério Lilenbaum
- Jules Lin
- Billy W. Loo
References
- SEER Cancer Statistics Review, 1975-2003
- Mutations of the BRAF gene in human cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer